Clinical trials: Stiff Person Syndrome
Stiff-Person Syndrome
Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome
This is a randomized double-blind controlled trial of intravenous immunoglobulin (IVIg) for glycine receptor antibody positive (GlyRα1) antibody Stiff Person Syndrome (SPS) spectrum disorders.
- Trial name
- NCT03749096
- Testing
- Intravenous Immunoglobulins, Human
- Where
- United States
- Sponsor
- Mayo Clinic
Stiff-Person Syndrome
Efgartigimod for Stiff Person Syndrome (ESPS)
The goal of this clinical trial is to examine the proportion of patients with stiff person syndrome with no worsening in stiffness and/or spasms while on efgartigimod-hyaluronidase (EFD) when compared to their current treatment.
- Trial name
- ESPS (NCT06528392)
- Testing
- Efgartigimod
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of South Florida
Stiff Person Syndrome
A Study Investigating Intravenous Human Normal Immune Globulin 10% in Adults With Stiff Person Syndrome
The purpose of this study is to evaluate the efficacy and safety of QIVIGY (Intravenous Human Normal Immune Globulin 10%) compared with placebo in adult participants with stiff person syndrome (SPS).
- Trial name
- NCT07552987
- Testing
- Kedrion IVIg 10%, Human Albumin
- Volunteers
- 38 people
- Sponsor
- Kedrion S.p.A.
Stiff-Person Syndrome
Stem Cell Transplantation for Stiff Person Syndrome (SPS)
Non-myeloablative regimens (as the investigators use herein) are designed to maximally suppress the immune system without destruction of the bone marrow stem cell compartment.
- Trial name
- SPS (NCT02282514)
- Testing
- Autologous Hematopoietic Stem Cells, Cyclophosphamide, Mesna
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Northwestern University
Muscle Rigidity, Spasm
Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS)
Stiff-man Syndrome (SMS) is a chronic, progressive disorder of the nervous system. It is associated with painful muscle spasms and rigidity involving muscles of the limbs, trunk, and neck.
- Conditions
- Muscle Rigidity, Spasm, Stiff Man Syndrome
- Trial name
- NCT00001550
- Testing
- IVIg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Stiff-Person Syndrome, SPS
KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Subjects with Treatment Refractory Stiff Person Syndrome
- Trial name
- NCT06588491
- Testing
- Standard lymphodepletion regimen
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Kyverna Therapeutics
Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD)
A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with central nervous system autoimmune diseases…
- Conditions
- Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), Autoimmune Encephalitis, Stiff Person Syndrome
- Trial name
- NCT07341828
- Testing
- CD20/BCMA-directed CAR-T cells
- Volunteers
- 15 people
- Sponsor
- Huashan Hospital
Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1
Baby Detect : Genomic Newborn Screening
Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions.
- Conditions
- Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1, Phosphoglucomutase 1 Deficiency, Maturity Onset Diabetes of the Young
- Trial name
- BabyDetect (NCT05687474)
- Where
- Belgium
- Volunteers
- 6,824 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Liege
Autoimmune Disease, Neurologic Autoimmune Disease
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic…
- Conditions
- Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant
- Trial name
- NCT00716066
- Testing
- Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Lupus Nephritis, Autoimmune Diseases
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
ADI-202300103 is a phase 1 multicenter, open label, dose finding and dose expansion, safety/efficacy study in patients with autoimmune disease.
- Conditions
- Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT06375993
- Testing
- ADI-001, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- Adicet Therapeutics
Stiff Person Syndrome
VYVGART (Hytrulo) in Patients With Stiff Person Syndrome (SPS)
Stiff Person Syndrome (SPS) is a rare autoimmune disorder, characterized by: a) incapacitating diffuse muscle stiffness prominent in the axial, abdominal and thoracolumbar paraspinal muscles leading to hyperlordosis, difficulty…
- Trial name
- NCT07860021
- Testing
- VYVGART Hytrulo
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Thomas Jefferson University
Stiff-Person Syndrome
Efficacy and Mechanism of Action of SCIg in Patients With Stiff Person Syndrome (SPS)
This is a pilot, proof-of concept investigator-initiated trial planned for 22 patients with the diagnosis of Stiff Person Syndrome (SPS).
- Trial name
- NCT03829826
- Testing
- HyQvia
- Volunteers
- 22 people
- Sponsor
- Thomas Jefferson University
Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 in adult participants with neurological autoimmune diseases (AIDs), including Progressive…
- Conditions
- Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Autoimmune Encephalitis
- Trial name
- CRSP-AID-502 (NCT07804004)
- Testing
- CTX112
- Volunteers
- 220 people
- Sponsor
- CRISPR Therapeutics
Stiff-Person Syndrome
Evaluating Spinal Cord Stimulation for Stiff Person Syndrome
The purpose of this prospective pilot study is to gather preliminary evidence evaluating spinal cord stimulation (SCS) as a potential therapy for the treatment of rigidity and painful spasms in patients with stiff person syndrome…
- Trial name
- NCT06242678
- Testing
- SCS trial lead
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Stiff Person Syndrome
Rituximab to Treat Stiff Person Syndrome
This study will test whether rituximab (RITUXAN (Trademark)) can relieve symptoms of stiff person syndrome (SPS), a progressive disease that causes stiffness of the muscles and muscle spasms induced by unexpected noises, touches…
- Trial name
- NCT00091897
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Autoimmune Encephalitis, Imbic Encephalitis
HLA Analysis in Autoimmune Encephalitis and Related Disorders
Autoimmune encephalitis (AE) are characterized by subacute onset of memory deficits, altered mental status or psychiatric symptoms, frequently associated with seizures, inflammatory cerebrospinal fluid and in cases with prominent…
- Conditions
- Autoimmune Encephalitis, Imbic Encephalitis, Autoimmune Cerebellar Ataxia, Stiff-person Syndrome
- Trial name
- ICARE (NCT04106596)
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Hospices Civils de Lyon
Stiff Person Syndrome
Extracorporeal Photopheresis (ECP) in the Treatment of Stiff Person Syndrome (OPTION Study)
OPTION study is a pilot, open-label, prospective, and multicentric clinical trial involving outpatients with a diagnosis of classical stiff person syndrome (SPS), whereas extracorporeal photopheresis (ECP) is the investigational…
- Trial name
- OPTION (NCT06703333)
- Testing
- Extracorporeal photopheresis (ECP)
- Where
- United Arab Emirates
- Sponsor
- Yandy Marx Castillo Aleman
Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder
Biomarkers in Autoimmune Disease of Nervous System
Neurological autoimmune diseases are a group of disorders characterized by the abnormal immune response attacking the nervous system, including the brain, spinal cord and peripheral nerves.
- Conditions
- Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Multiple Sclerosis, Guillain-Barre Syndrome
- Trial name
- NCT06502015
- Testing
- biomaker levels
- Where
- China
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Refractory Lupus Nephritis, Myasthaenia Gravis
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been…
- Conditions
- Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA)
- Trial name
- KYSA-4 (NCT07403188)
- Testing
- KYV-101
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Kyverna Therapeutics
Stiff-Person Syndrome
Cause, Development, and Progression of Stiff-Person Syndrome
This study will explore the role of various immune factors involved in producing the disease symptoms in stiff-person syndrome (SPS) and follow disease progression in patients.
- Trial name
- NCT00030940
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)